Purpose. To compare the therapeutic results of two radiotherapy (RT) dose schedules in combined temozolomide- (TMZ-)\nRT treatment in newly diagnosed glioblastoma (GB), according to the O(6)-methylguanine-DNA methyltransferase (MGMT)\nmethylation status. Material and Method. Patients received either standard (60Gy) or moderately escalated dose (70Gy)\nradiotherapy (RT) with concomitant and adjuvant TMZ between June 2006 and October 2013. We retrospectively evaluated the\ntherapeutic effectiveness of RT schedules in terms ofOverall Survival (OS) and Progression-Disease Free Survival (PDFS) analyzing\nthe MGMT methylation status. Results. One hundred and seventeen patients were selected for the present analysis. Seventy-two\nout of the selected cases received the standard RT-TMZ course (SDRT-TMZ) whereas the remaining 45 underwent the escalated\nschedule (HDRT-TMZ). The analysis according to theMGMT promoter methylation status showed that, in unmethylated-MGMT\nGB patients, HDRT-TMZ and SDRT-TMZ groups had differentmedian OS (
Loading....